Based on the findings showing suppression of BRCA2 expression upon MEK inhibition, we sought to investigate whether impaired HR caused by pimasertib in BRCA-proficient ovarian cancer cells would result in increased DNA damage following PARP inhibition. The gene discussed is BRCA2; the disease is ovarian carcinoma.